Online Now: Cooperative CAR targeting to selectively eliminate AML and minimize escape dlvr.it/Sx529Z

Heading west to a fantastic meeting with Wajma Shahbaz! #ASH23

My first in-person ASH after a 3-year hiatus. Great to be inspired by the atmosphere of innovation, and to connect with colleagues & friends! Tobias Herold Christian Rausch Simon Krauß #ASH23

Very proud to have contributed to this massive effort of #ctDNA profiling of classic Hodgkin lymphoma published in nature today during #ASH23 Mohammad Shahrokh Esfahani #AndreaGarofalo #MichaelYuLi Ash Alizadeh, MD/PhD 🇺🇸 Max Diehn, MD/PhD

Big credits to Christian Rausch excellent poster presentation at #ASH23 on RUNX1 mutated AML!

Well done Wajma Shahbaz ! Congratulations to the first oral presentation at #ASH23 on the DDX41 low expression subgroup.

Great oral presentation by David Cordas dos Santos at ASH2023 and congratulations to Kai Rejeski and Tobias Tix for initiating this important study!

📄Only #AML patients with typical in-frame InDel #CEBPA bZIP mutations had higher rates of complete remission and longer RF & OS. For all other pts grouping according to #ELN2022 recommendations added significant prognostic information nature.com/articles/s4137…

How risky are central venous catheters? jwat.ch/3Txps1W #HospitalMedicine #MedTwitter

Ibrutinib combined with immunochemotherapy with or without autologous SCT vs immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with MCL (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial thelancet.com/journals/lance…

After hearing David Beck's discovery of UBA1 mutations in VEXAS Maria Sirenko Elsa Bernard in collaboration Maria Creignou & David, set out to investigate the role of UBA1 mutations in MDS patients lacking clinically relevant mutations. Read more in Blood Journal this week👇

Our manuscript on molecular subtypes in adult T-ALL is out in Leukemia Journal ! Gene expression based subtypes have distinct outcomes in #GMALL patients. Congrats to Martin Neumann, Claudia Baldus and our team Universitätsklinikum Schleswig-Holstein and Universität Kiel CAU 🎓 ! (rdcu.be/dHWa8)

1/13 I’m very happy to share our article on multi-omics in acute coronary syndromes published in Nature Medicine nature.com/articles/s4159… with you!

A helpful article diving into the nuance of KMTAr AML and outcomes! -KRAS, TP53, or DNMT3A co-mutations with particularly poor outcomes nature.com/articles/s4137…

Just out Nature Medicine meta-analysis >7600 CAR T pts led by David Cordas dos Santos & Kai Rejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection nature.com/articles/s4159…

Check out our new study in Nature Medicine looking at nonrelapse mortality after CAR-T cell treatment with Tobias Tix and Kai Rejeski nature.com/articles/s4159…

Nature research paper: Plasmacytoid dendritic cells control homeostasis of megakaryopoiesis go.nature.com/4cU7gX7

Evans syndrome is a rare disease marked by a severe clinical course and sometimes fatal outcome. Management is highly heterogeneous. Read the first consensus recommendations for the diagnosis and management of Evans syndrome in adults thelancet.com/journals/lanha…

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…